79th World Health Assembly (WHA79): Rare diseases: A global health priority for equity and inclusion
On 22 May 2026, IFPMA published a statement on rare diseases on the margins of the 79th session of the World Health Assembly in Geneva.
IFPMA strongly supports the implementation of a Global Action Plan for Rare Diseases. This plan represents a unique opportunity to close long-standing gaps in access to specialized care, while reinforcing health systems and advancing Universal Health Coverage.
The innovative pharmaceutical industry stands ready to work in partnership with WHO, governments, patients, clinicians, and all stakeholders across the rare disease ecosystem. Key to this collaboration is:
- Developing global diagnostic guidance to reduce inequalities in early access to diagnosis and therapeutic opportunities
- Strengthening rare disease data systems that enable medical advances and improve efficiency across health systems, both for rare diseases and for common conditions.
IFPMA looks forward to contributing to the industry’s expertise to the Global Action Plan and urges the WHO to initiate the process.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
Why orphan medicines remain out of reach in low- and middle-income countries – and what can be done
Rare diseases, comprised of more than 7,000 conditions, are a major global health challenge, affecting over 300 million people worldwide. In low- and middle-income countries (LMICs), the burden is substantial and likely underestimated due to underdiagnosis, weak surveillance, and limited access to early diagnosis and preventive care. Even where treatments exist, access to orphan medicines...
Read more
158th session of the WHO Executive Board (EB158): Co-creating the Global Action Plan for rare diseases
On 3 February 2026, IFPMA delivered a statement on Agenda item 9: Co-creating the Global Action Plan for rare diseases at the 158th session of the WHO Executive Board. IFPMA commends Member States and the WHO for implementing the 2025 WHA Resolution on Rare Diseases and strongly supports the prompt initiation of a Global Action...
Read moreIFPMA welcomes the adoption of the WHA78 Resolution on rare diseases
On 24 May 2025, a resolution on rare diseases was adopted at the 78th session of the World Health Assembly. IFPMA issued a statement in support of the resolution. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with its member companies and associations, welcomes the adoption of the World Health Assembly (WHA) Resolution...
Read more